WHAT IS CLAIMED IS:

1. A compound of formula (I)-(IX), or a pharmaceutically acceptable salt or prodrug thereof,



(I)



(II)



(III)



(IV)



(V)



(VI)



(VII)



(VIII)



(IX)

R^1 is H, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} deuteroalkyl,or halo;

R^2 is H, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} deuteroalkyl, C_{1-4} deuteroalkoxy, halo, or NH_2;

R is H, Cl, F, Br, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} deuteroalkyl, C_{1-4} deuteroalkoxy, cyclopropyl, or $N(R^a)_2$:

R^a is H, C_{1-4} alkyl, C_{1-4} deuteroalkyl, or C_{3-6} cycloalkyl;

L is –NH, -NR^b, , , , or ;

R^b is H, C_{1-4} alkyl, C_{1-4} deuteroalkyl, C_{3-6} cycloalkyl, (phosphonooxy)alkyl, ((phosphonooxy)alkylcarbonyloxy)alkyl, ((amino)alkylcarbonyloxy)alkyl, ((amino)cycloalkylcarbonyloxy)alkyl, ((((phophonooxy)alkyl)carbonyloxy)alkyl)oxycarbonyl ((((phophonooxy)cycloalkyl)carbonyloxy)alkyl)oxycarbonyl; ((((amino)alkyl)carbonyloxy)alkyl)oxycarbonyl, ((((amino)cycloalkyl)carbonyloxy)alkyl)oxycarbonyl, or ((((phosphonooxy)(alkoxy)benzoyl)alkyl)oxycarbonyl;

R^c is C_{1-3} alkyl, or C_{1-3} haloalkyl;

A is absent, -S-, C_{1-6} alkyl substituted with 0-1 OH, C_{1-6} deuteroalkyl substituted with 0-1 OH, C_{1-6} haloalkyl substituted with 0-1 OH, C_{1-6} alkyl-O-, C_{1-6} deuteroalkyl-O-, C_{1-6} haloalkyl-O-, C_{3-6} cycloalkyl-C_{1-3}-alkyl-, C_{1-3}-alkyl-C_{3-6} cycloalkyl-, C_{1-3}-alkylcarbonyl, -pyrrolyl-C_{1-3}-alkyl-, -C_{1-3}-alkyl-pyrrolyl-, -pyrrolidinyl-C_{1-3}-alkyl-, or -C_{1-3}-alkyl-pyrrolidinyl-;

R^3 is C_{6-10} aryl, $CH(aryl)_2$, 5- or 6-membered heteroaryl, or 5 to 10 membered heterocycle having 1-4 heteroatoms selected from N, O, and S, wherein any of aryl, heteroaryl, or heterocycle groups are substituted with 0-3 R^4;

R^4 is halo, C_{1-6} alkyl, C_{1-6} (C_{1-6} alkoxy)alkyl, C_{1-6} (C_{6-10} aryl)alkyl, C_{1-6} alkoxy, C_{1-6} (C_{3-7} cycloalkyl)alkoxy, C_{1-6} deuteroalkyl, C_{1-6} deuteroalkoxy, C_{1-6} (C_{3-7} cycloalkyl)deuteroalkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-7} cycloalkoxy, C_{3-7} cycloalkyl, C_{6-10} aryl, C_{6-10} aryloxy, 5- or 6-membered heteroaryl, -S-C_{1-6}alkyl, -S-C_{1-6} haloalkyl, -S-C_{6-10} aryl, -SO_2-C_{1-6} alkyl, -SO_2-C_{6-10} aryl, -SO_2-heterocycle, -O-heterocycle, -(CO)-hetercycle, -$(CH_2)_n$-hetercycle, or O-C(O)-N$(R^a)_2$, wherein each heterocycle is independently a 3-10 membered ring having 1-4 heteroatoms selected from N, O, and S, and wherein each heterocycle, aryl, or heteroaryl is substituted with 0-2 R^5;

R^5, at each occurrence, is independently C_{1-4} alkyl, halo, =O, C_{1-4} hydroxyalkyl;

n is 1-3; and

m is 0 or 1.

2. A compound of claim 1 where

where

R^1 is H, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} deuteroalkyl, or halo;

R^2 is H, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} deuteroalkyl, C_{1-4} deuteroalkoxy, halo, or NH_2;

R is H, Cl, F, Br, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} deuteroalkyl, C_{1-4} deuteroalkoxy, cyclopropyl, or $N(R^a)_2$:

R^a is H, C_{1-4} alkyl, C_{1-4} deuteroalkyl, or C_{3-6} cycloalkyl;

L is –NH,-NR^a, , , , or ;

R^c is C_{1-3} alkyl, or C_{1-3} haloalkyl;

A is C_{1-6} alkyl substituted with 0-1 OH, C_{1-6} deuteroalkyl substituted with 0-1 OH, C_{1-6} haloalkyl substituted with 0-1 OH, C_{1-6} alkyl-O-, C_{1-6} deuteroalkyl-O-, C_{1-6} haloalkyl-O-, C_{3-6} cycloalkyl-C_{1-3}-alkyl-, C_{1-3}-alkyl-C_{3-6} cycloalkyl-, -pyrrolyl-C_{1-3}-alkyl-, -C_{1-3}-alkyl-pyrrolyl-, -pyrrolidinyl-C_{1-3}-alkyl-, or -C_{1-3}-alkyl-pyrrolidinyl-;

R^3 is C_{6-10} aryl, $CH(aryl)_2$, or a 5 to 10 membered heterocycle having 1-4 heteroatoms selected from N, O, and S, wherein any of aryl or heteroaryl groups are substituted with 0-3 R^4;

R^4 is halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} deuteroalkyl, C_{1-6} deuteroalkoxy,C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-7} cycloalkoxy, C_{3-7} cycloalkyl, C_{6-10} aryl, C_{6-10} aryloxy, -S-C_{1-6}alkyl, -S-C_{1-6} haloalkyl, -S-C_{6-10} aryl, -SO_2-C_{1-6} alkyl, -SO_2-C_{6-10} aryl, -SO_2-heterocycle, -O-heterocycle, or -$(CH_2)_n$-hetercycle, O-C(O)-$N(R^a)_2$, wherein each heterocycle is independently a 3-10 membered ring having 1-4 heteroatoms selected from N, O, and S, and wherein each heterocycle or aryl is substituted with 0-2 R^5;

R^5, at each occurrence, is independently C_{1-4} alkyl, halo, =O, or C_{1-4} hydroxyalkyl; and

m is 0 or 1.

3. A compound of claim 1, or salt thereof, wherein

R^3 is C_{6-10} aryl, $CH(phenyl)_2$, or a heterocycle having 1-4 heteroatoms selected from N, O, and S, wherein any of aryl or heteroaryl groups are substituted with 0-3 R^4, and wherein the heterocycle is selected from pyridyl, pyridinyl, or pyrrolyl.

4. A compound of claims 1-2, or salt thereof, wherein

A is C_{1-4} alkyl substituted with 0-1 OH, C_{1-4} deuteroalkyl substituted with 0-1 OH, C_{1-4} haloalkyl substituted with 0-1 OH, C_{1-4} alkyl-O-, C_{1-4} deuteroalkyl-O-, C_{1-4} haloalkyl-O-, C_{3-6} cycloalkyl-C_{1-3}-alkyl-, C_{1-3}-alkyl-C_{3-6}

cycloalkyl-,-pyrrolyl-C_{1-3}-alkyl-, C_{1-3}-alkyl-pyrrolyl-, -pyrrolidinyl-C_{1-3}-alkyl-, or C_{1-3}-alkyl-pyrrolidinyl-.

5. A compound of claims 1-3, or salt thereof, wherein

R^3 is phenyl, $CH(phenyl)_2$, or a 5 to 10 membered heterocycle having 1-4 heteroatoms selected from N, O, and S, wherein any of aryl or heteroaryl groups are substituted with 0-3 R^4, and wherein the heterocycle is selected from pyridyl, pyridinyl, or pyrrolyl.

6. A compound of claims 1-4, or salt thereof, wherein

A is -C_{1-4} alkyl- substituted with 0-1 OH, -C_{1-4} deuteroalkyl, -C_{1-4} alkyl-O-, -C_{1-4} deuteroalkyl-O-, -C_{3-6} cycloalkyl-C_{1-3}-alkyl-, -pyrrolyl-C_{1-3}-alkyl-, C_{1-3}-alkyl-pyrrolyl-, -pyrrolidinyl-C_{1-3}-alkyl-, or -C_{1-3}-alkyl-pyrrolidinyl-.

7. A compound of claims 1-4, or salt thereof, wherein R^1 is H, or C_{1-4} alkyl;

R^2 is H, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} deuteroalkyl, C_{1-4} deuteroalkoxy, halo, or NH_2;

R is H, Cl, F, Br, C_{1-4} alkyl, C_{1-4} alkoxy, cyclopropyl, or NR^a_2,

R^a is H, C_{1-4} alkyl, or C_{1-4} deuteroalkyl.

8. A compound of claims 1-6, or salt thereof, wherein

R^4 is halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} deuteroalkyl, C_{1-6} deuteroalkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-7} cycloalkoxy, or C_{3-7} cycloalkyl.

9. A Compound of claims 1-7, wherein the the compound is of formula (I), or salt thereof



(I).

10. Compound of claims 1-7, wherein the the compound is of formula (II), or salt thereof



(II).

11. Compound of claims 1-7, wherein the the compound is of formula (III), or salt thereof



(III).

12. A compound of claim 1, wherein the compound is selected from the examples.

13. A pharmaceutical composition comprising one or more compounds of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. Compound of claim 1 for use in the treatment of inhibiting casein kinase RIPK1 activity in a patient, wherein a therapeutically effective amount of the compound is to be administered to the patient in need thereof.

15. Compound of claims 1-11 for use in the treatment of a disease, wherein a therapeutically-effective amount of the compound is to be administered to a subject in need thereof, wherein the disease is selected from inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, rheumatoid arthritis (RA), NASH, and heart failure.

16. Use of compound of claim 1 in the manufacture of a medicament for the treatment of inhibiting casein kinase RIPK1 activity in a patient, wherein a therapeutically effective amount of the medicament is to be administered to the patient in need thereof.

17. Use of compound of claims 1-11 in the manufacture of a medicament for the treatment of a disease, wherein a therapeutically-effective amount of the medicament is to be administered to a subject in need thereof, wherein the disease is selected from inflammatory bowel disease, ulcerative colitis, Crohn’s disease, psoriasis, rheumatoid arthritis (RA), NASH, and heart failure.